Pain Management Therapeutics Market 2021 to 2030 – Industry Scope and Growth Strategies by Key Players, Drug Class, Indication, Distribution Channel and Geography

According to Precedence Research, the pain management therapeutics market size is forecasted to reach around US$ 105.77 billion by 2030, growing at a 4.3% CAGR from 2021 to 2030.

Pain is a strong physical feeling triggered due to tissue injury or ailment. Pain not only influences the physical but also mental well-being of a person. The pain intensity instigated owing to tissue injury or trauma entirely depends on individual to individual. The treatment depends on the level of the injury or ailment. Various disorders such as cancer, diabetic neuropathy, osteoarthritis, and numerous acute ailments results in pain. Chronic and acute are the two main categories of pain segregated on the basis of pain duration.

Short term pain is termed as acute pain whereas long duration pain which is triggered due to numerous chronic ailments is termed as chronic pain. The pain management therapeutics domain includes the contraction and treatment of pain with the use of various groupings of drugs and workouts which deliver relief to the sufferer by directing at the receptors. The demand for pain management has seen an exponential rise mainly due to changing lifestyle patterns and growing number of chronic ailments.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1224

Growth Factors:

Factors such as increasing geriatric population, rising number of accidents worldwide, growing prevalence of chronic disorders, rise in per-capita healthcare expenditure, increasing number of surgeries, constant approvals for new easy-to-use and effective medications, increasing cases of cancer in developing regions, and growing research and development expenditure are propelling the pain management therapeutics market expansion across the globe. Additional aspects that are estimated to fuel this industry are strong product pipeline of major manufacturers and technological innovations. A constant rise in the cases of chronic disorders throughout the world is pushing the business to grow at a rapid pace. Early detection of ailment raises the chances for a decreased mortality rate. According to the American Cancer Society, around 1.76 million new cancer cases were diagnosed in 2019 and more than 606,000 cancer deaths reported in the United States alone. The number of elderly persons is also on the rise globally. According to the World Health Organization, the geriatric population is projected to hit 1.5 billion by the year 2040, which will represent around 16% of the entire world population.

Growing investment in the research and development activities aimed at improving the efficiency of existing therapy options along with developing new treatments is driving the market globally. The short-term as well as long-term strategies of leading biotech and pharma companies play a vital role in determining market trends. Short term policies aim at tackling patenting concerns and display an immediate effect on the market. Whereas, long term policies focus on upgrading R&D, focused treatment approaches, and unified network representations.

Market Scope:

Report Highlights Details
Market Size USD 105.77 Billion by 2030
Growth Rate CAGR of 4.3% from 2022 to 2030
Base Year 2021
Historic Data 2017 to 2021
Forecast Period 2022 to 2030
Segments Covered Drug Class, Indication, Distribution Channel
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The pain management therapeutics report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Report Highlights:

  • Among the drug class segment, NSAIDs dominated the overall market in 2020. High efficiency and ease of availability are the major reason for high market share of NSAIDs in pain management therapeutics.
  • The neuropathic pain segment accounted for the largest revenue within the indication segment with more than 32% share in 2020. Factors such as large patient pool and technological innovations drive the growth of interventional study. Chronic back pain and cancer pain indications are projected to grow at significant rate in the forecast time-frame.
  • Retail pharmacy accounted for the largest revenue in the distribution channel segment. High use of over-the-counter drugs for pain management is the key reason for high market share of retail pharmacies.
  • Pfizer, Teva Pharmaceutical, and AstraZeneca accounted for a significant share of the global pain management therapeutics market.

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2020, North America dominated the global market with a market share of more than 43%. U.S. represented the highest share in the North American region primarily due to presence of leading market players and high incidence of cancer. Furthermore, increasing geriatric population also contributed to the high market share of the United States.

Europe was the second important market chiefly due to favorable reimbursement scenario and rise in number of cases of drug abuse. High incidence of chronic disorders in the European region is also expected to boost the demand for pain management therapeutics market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around5.8% in the forecast period due to high number of accidents and increasing healthcare expenditure. Latin America and the African and Middle Eastern region will display noticeable growth.

 

Key Players:

The pain management therapeutics market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the pain management therapeutics market include:

  • Teva Pharmaceutical
  • Pfizer
  • Abbott
  • Mallinckrodt Pharmaceuticals
  • Endo International
  • GlaxoSmithKline
  • AstraZeneca
  • Depomed
  • Merck
  • Novartis

Market Segmentation

By Drug Class

  • NSAIDs
  • Opioids
  • Anesthetics
  • Antidepressants
  • Anticonvulsants
  • Others

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Chronic Back Pain
  • Post-Operative Pain
  • Cancer Pain
  • Others

By Distribution Channel

  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy

Regional Segmentation

  • North America (U.S. and Canada)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pain Management Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pain Management Therapeutics Market

5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pain Management Therapeutics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements

Chapter 7. Global Pain Management Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pain Management Therapeutics Market, By Drug Class

8.1. Pain Management Therapeutics Market, by Drug Class, 2017 – 2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017 – 2030)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2017 – 2030)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2017 – 2030)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2017 – 2030)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2017 – 2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017 – 2030)

Chapter 9. Global Pain Management Therapeutics Market, By Indication

9.1. Pain Management Therapeutics Market, by Indication, 2017 – 2030
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2017 – 2030)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2017 – 2030)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2017 – 2030)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2017 – 2030)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2017 – 2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017 – 2030)

Chapter 10. Global Pain Management Therapeutics Market, By Distribution Channel

10.1. Pain Management Therapeutics Market, by Distribution Channel, 2017 – 2030
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2017 – 2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017 – 2030)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2017 – 2030)

Chapter 11. Global Pain Management Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Drug Class(2017 – 2030)
11.1.2. Market Revenue Forecast by Indication(2017 – 2030)
11.1.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017 – 2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017 – 2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.2.2. Market Revenue Forecast by Indication (2017 – 2030)
11.2.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017 – 2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017 – 2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017 – 2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017 – 2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.3.2. Market Revenue Forecast by Indication (2017 – 2030)
11.3.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017 – 2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017 – 2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017 – 2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017 – 2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.4.2. Market Revenue Forecast by Indication (2017 – 2030)
11.4.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017 – 2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017 – 2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class (2017 – 2030)
11.5.2. Market Revenue Forecast by Indication (2017 – 2030)
11.5.3. Market Revenue Forecast by Distribution Channel (2017 – 2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017 – 2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017 – 2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017 – 2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017 – 2030)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin (2017 – 2020)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1224

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.